Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series A. The raise follows a $4M seed in February — taking its total raised to date to $20M. Put simply, Mogrify’s approach entails analysis of vast […]...